You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 5,770,619


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,770,619
Title: Method of activating photosensitive agents
Abstract:A method of administering photodynamic therapy begins with administering to an animal an effective amount of a photosensitizing agent which is less than about one half of the usual clinical dose for the photosensitizing agent. Then, following a post injection interval which is less about one quarter of the usual post injection interval, an effective dose of light which is less than about one half of the usual clinical dose of light used in conjunction with the photosensitizing agent is administered to the animal.
Inventor(s): Richter; Anna M. (Vancouver, CA), Waterfield; Elizabeth (Vancouver, CA), Levy; Julia G. (Vancouver, CA)
Assignee: University of British Columbia (Vancouver, CA)
Application Number:08/551,471
Patent Claims: 1. A method to destroy or impair an area of neovascularization in an animal, which animal comprises both an area of neovascularization and normal tissue, which method comprises:

(a) administering to said animal an effective amount of a photosensitizing agent;

(b) administering to said area of neovascularization an effective amount of light of a wavelength that matches an excitation wavelength of said photosensitizing agent,

wherein said light is administered to said area of neovascularization before said photosensitizing agent has permeated said normal tissue.

2. The method of claim 1, wherein the time between step (a) and step (b) is less than one quarter of the clinical interval for subjecting the animal to light treatment after administering said photosensitizing agent.

3. The method of claim 1 wherein the effective amount of the photosensitizing agent is approximately less than one half of the clinical dose of said photosensitizing agent in photodynamic therapy.

4. The method of claim 1 wherein the effective amount of light is less than about half of the clinical dose of light for activation of the photosensitizing agent in photodynamic therapy.

5. The method of claim 1 herein the photosensitizing agent is selected from the group consisting of a chlorin, a bacteriochlorin, a phthalocyanine, a porphyrin, a purpurin, a merocyanine, a pheophorbide and a psoralen.

6. The method of claim 5 wherein said photosensitizer is a porphyrin.

7. The method of claim 6 wherein the porphyrin is BPD or porfimer sodium.

8. The method of claim 7 wherein the porphyrin is BPD-MA.

9. The method of claim 1 wherein the animal is mammal.

10. The method of claim 9 wherein the mammal is a human.

11. The method of claim 8 wherein the postinjection time varies between about one minute and 45 minutes.

12. A method to destroy or impair an area of neovascularization in an animal, which animal comprises both an area of neovascularization and normal tissue, which method comprises:

(a) administering to said animal an effective amount of benzoporphyrin derivative-monoacid (BPD-MA); and

(b) administering to said area of neovascularization an effective amount of light of a wavelength that matches an excitation wavelength of said BPD-MA,

wherein said light is administered to said area of neovascularization before said BPD-MA has permeated said normal tissue;

and wherein the time between step (a) and (b) varies between about one minute and 45 minutes.

13. The method of claim 12 wherein said area of neovascularization is a solid tumor.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.